Yamamoto, T., Kanaya, N., Somlo, G., & Chen, S. (2019). Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer. Breast Cancer Res Treat.
Chicago-stil citatYamamoto, Takuro, Noriko Kanaya, George Somlo, och Shiuan Chen. "Synergistic Anti-cancer Activity of CDK4/6 Inhibitor Palbociclib and Dual MTOR Kinase Inhibitor MLN0128 in PRb-expressing ER-negative Breast Cancer." Breast Cancer Res Treat 2019.
MLA-referensYamamoto, Takuro, Noriko Kanaya, George Somlo, och Shiuan Chen. "Synergistic Anti-cancer Activity of CDK4/6 Inhibitor Palbociclib and Dual MTOR Kinase Inhibitor MLN0128 in PRb-expressing ER-negative Breast Cancer." Breast Cancer Res Treat 2019.